Logo image of TCRT

ALAUNOS THERAPEUTICS INC (TCRT) Stock Fundamental Analysis

NASDAQ:TCRT - Nasdaq - US98973P3091 - Common Stock - Currency: USD

1.68  +0.07 (+4.35%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TCRT. TCRT was compared to 571 industry peers in the Biotechnology industry. The financial health of TCRT is average, but there are quite some concerns on its profitability. TCRT has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TCRT has reported negative net income.
TCRT had a negative operating cash flow in the past year.
In the past 5 years TCRT always reported negative net income.
In the past 5 years TCRT always reported negative operating cash flow.
TCRT Yearly Net Income VS EBIT VS OCF VS FCFTCRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M

1.2 Ratios

With a Return On Assets value of -331.86%, TCRT is not doing good in the industry: 95.91% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -432.49%, TCRT is doing worse than 78.86% of the companies in the same industry.
Industry RankSector Rank
ROA -331.86%
ROE -432.49%
ROIC N/A
ROA(3y)-188.79%
ROA(5y)-145.8%
ROE(3y)-263.55%
ROE(5y)-195.83%
ROIC(3y)N/A
ROIC(5y)N/A
TCRT Yearly ROA, ROE, ROICTCRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

TCRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRT Yearly Profit, Operating, Gross MarginsTCRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200K -400K -600K

More info and screens

6

2. Health

2.1 Basic Checks

TCRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
TCRT has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, TCRT has more shares outstanding
TCRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCRT Yearly Shares OutstandingTCRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
TCRT Yearly Total Debt VS Total AssetsTCRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -366.72, we must say that TCRT is in the distress zone and has some risk of bankruptcy.
TCRT's Altman-Z score of -366.72 is on the low side compared to the rest of the industry. TCRT is outperformed by 98.93% of its industry peers.
There is no outstanding debt for TCRT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -366.72
ROIC/WACCN/A
WACC18.61%
TCRT Yearly LT Debt VS Equity VS FCFTCRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

TCRT has a Current Ratio of 4.30. This indicates that TCRT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.30, TCRT is in line with its industry, outperforming 48.85% of the companies in the same industry.
TCRT has a Quick Ratio of 4.30. This indicates that TCRT is financially healthy and has no problem in meeting its short term obligations.
TCRT has a Quick ratio (4.30) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.3
Quick Ratio 4.3
TCRT Yearly Current Assets VS Current LiabilitesTCRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.19% over the past year.
Looking at the last year, TCRT shows a very negative growth in Revenue. The Revenue has decreased by -60.00% in the last year.
TCRT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -49.08% yearly.
EPS 1Y (TTM)15.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.8%
Revenue 1Y (TTM)-60%
Revenue growth 3YN/A
Revenue growth 5Y-49.08%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TCRT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.82% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.33%
EPS Next 2Y42.77%
EPS Next 3Y25.86%
EPS Next 5Y14.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCRT Yearly Revenue VS EstimatesTCRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
TCRT Yearly EPS VS EstimatesTCRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150 -200

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TCRT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 1.92, the valuation of TCRT can be described as very cheap.
Based on the Price/Forward Earnings ratio, TCRT is valued cheaply inside the industry as 99.47% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, TCRT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.92
TCRT Price Earnings VS Forward Price EarningsTCRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRT Per share dataTCRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

TCRT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TCRT's earnings are expected to grow with 25.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.77%
EPS Next 3Y25.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TCRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALAUNOS THERAPEUTICS INC

NASDAQ:TCRT (2/21/2025, 8:00:01 PM)

1.68

+0.07 (+4.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-31 2025-03-31/amc
Inst Owners4.51%
Inst Owner Change-93.76%
Ins Owners13.78%
Ins Owner Change-0.12%
Market Cap2.69M
Analysts43.33
Price TargetN/A
Short Float %4.76%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.92
P/S 448
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)-22.9
EYN/A
EPS(NY)0.88
Fwd EY52.21%
FCF(TTM)-7.35
FCFYN/A
OCF(TTM)-7.35
OCFYN/A
SpS0
BVpS1.7
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -331.86%
ROE -432.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.79%
ROA(5y)-145.8%
ROE(3y)-263.55%
ROE(5y)-195.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.3
Quick Ratio 4.3
Altman-Z -366.72
F-Score5
WACC18.61%
ROIC/WACCN/A
Cap/Depr(3y)48.1%
Cap/Depr(5y)211.26%
Cap/Sales(3y)1594.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.8%
EPS Next Y97.33%
EPS Next 2Y42.77%
EPS Next 3Y25.86%
EPS Next 5Y14.82%
Revenue 1Y (TTM)-60%
Revenue growth 3YN/A
Revenue growth 5Y-49.08%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y68.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.4%
OCF growth 3YN/A
OCF growth 5YN/A